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Abstract
The secretion of aldosterone by the adrenal cortex is a tightly regulated process. 
Loss of this control can result in severe hypertension and end-organ damage, so 
detailed understanding of the various mechanisms by which the body regulates 
aldosterone biosynthesis is key. The emergence of microRNAs (miRNAs) as nega-
tive regulators of numerous physiological processes has naturally led to their study 
in the context of aldosterone production. We summarise several studies that have 
demonstrated a significant role for microRNAs in aldosterone biosynthesis and 
action, thereby presenting a possible therapeutic role in the treatment of common 
forms of hypertension such as primary aldosteronism. Furthermore, the presence 
of microRNAs in the circulation offers the prospect of accessible and informative 
biomarkers that may simplify the currently protracted and technically difficult 
diagnosis of such conditions.
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1. Introduction
High blood pressure, or hypertension, is a major risk factor for coronary disease, 
heart failure and stroke. Hypertension is a contributing factor in over 7 million 
deaths per year, which provides strong motivation to understand the systems 
regulating normal blood pressure and how such control can be lost. Our own stud-
ies have focused on the role of the hormone aldosterone, a key determinant of blood 
pressure, and the various factors regulating its secretion from the adrenal gland.
Aldosterone is synthesised in the adrenal cortex and acts on specific mineralo-
corticoid receptors (MR), principally in epithelial tissue, to regulate fluid balance, 
electrolyte homeostasis and blood pressure. Excess secretion of aldosterone, 
as in primary aldosteronism (PA), leads to severe hypertension with markedly 
increased risk of myocardial infarction, stroke and left ventricular hypertrophy [1]. 
Originally believed to be a rare condition (principally due to practical difficulties 
in accurate diagnosis), the reported frequency of PA in all hypertensives has risen 
steadily over the years and is now generally regarded to lie somewhere between 10 
and 20%; PA is therefore the single most common form of secondary hyperten-
sion [2]. Independent of its effects on blood pressure, excess aldosterone also has 
detrimental effects on various target organs including the renal and cardiovascular 
systems [3]. Such negative effects are not necessarily confined to PA; even when 
present in minimal excess, aldosterone associates with higher blood pressure and 
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
2
substantial cardiovascular morbidity [4]. Although major advances have been made 
in understanding aldosterone and its regulation in the 60 years since its discovery, 
many aspects remain incompletely understood. New factors capable of regulating 
aldosterone secretion are still emerging, and evidence generated by ourselves and 
others indicate that we must add microRNA (miRNA) to this list.
In this article we summarise the major findings to date regarding miRNA and its 
effects on aldosterone secretion and action. We also anticipate the future direction 
and outcomes of such studies—including the possible role for miRNA in the accu-
rate diagnosis of PA and other subtypes of hypertension—and related therapeutic 
strategies that could be employed to modify hormone production and action in such 
patients to yield major health benefits.
2. Aldosterone biosynthesis
Aldosterone biosynthesis is confined to the adrenocortical zona glomerulosa 
(ZG) and in normal circumstances is principally controlled by the renin-angiotensin 
system (RAS) and potassium status. Synthesis consists of a series of enzymatic 
reactions commencing with the conversion of cholesterol by the side-chain cleavage 
enzyme, CYP11A1. The terminal reactions in aldosterone biosynthesis are catalysed 
by the enzyme aldosterone synthase, the product of the CYP11B2 gene, which is 
expressed only in the ZG. Its expression is principally controlled by angiotensin 
II (AngII) and potassium through transcription factor binding of its 5′ regulatory 
region [5]. The key second messenger in this process is calcium; influx of Ca2+ 
through channels in the ZG cell membrane raises aldosterone production by various 
means that include stimulation of CYP11B2 transcription and increased availability 
of the cofactor NADH. Extensive study of the CYP11B2 gene has shown it to be 
highly polymorphic, with multiple genetic sequence variations present across its 
introns and in the untranslated regions (UTRs) lying to the 5′ and 3′ ends of the 
locus. Certain of these 5′ and intronic variants associate with altered gene activity 
and also with raised plasma aldosterone, increased urinary excretion of aldosterone 
metabolites and high blood pressure, demonstrating that relatively subtle changes 
in expression of this gene can have significant cardiovascular effects. The discovery 
of microRNAs and their role in post-transcriptional repression of specific genes, 
principally through sites located in the 3’ UTR, has now focused interest on that 
region of CYP11B2.
3. MicroRNA
miRNAs are a class of endogenous, small (~20–25 nucleotides), single-stranded 
non-coding RNA molecules which act to post-transcriptionally regulate expression 
of specific target mRNAs. They are often regarded as having only subtle ‘fine-
tuning’ roles in gene expression but are nevertheless capable of significant effects 
including roles in human disease, including numerous cancers [6, 7].
Synthesis of miRNA is a multistep process (see Figure 1), beginning with the 
transcription in the nucleus from miRNA genes located mainly in intergenic or 
intronic chromosomal regions of chromosomes, although some are also pres-
ent in exons [8, 9]. This produces primary transcripts (pri-miRNA), which are 
processed by Drosha endonuclease into pre-miRNAs ~70 nucleotides in size. Due 
to self-complementary nucleotide binding, these pre-miRNAs have distinctive 
‘hairpin loop’ structures and are transported by Exportin-5 from the nucleus to the 
cytoplasm, where they are processed further by Dicer to form a miRNA duplex. 
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The strand of the miRNA duplex with lower thermodynamic stability (usually the 
3′ arm) is termed the passenger strand; this is removed, resulting in the formation 
of the mature miRNA [10]. It was initially thought that the passenger strand had 
no biological function and was automatically targeted for degradation, but recent 
studies show that passenger strands can have a functional role in mRNA regulation, 
prompting their study in current miRNA research [11, 12]. The mature miRNA 
then recruits a ribonucleoprotein complex called the miRNA-induced silenc-
ing complex (miRISC). At the core of the mammalian miRISC is one of the four 
Argonaute proteins (AGO1–4) and a 182 kDa protein, GW182. While the miRNA 
sequence determines which mRNAs are targeted for repression, it is the miRISC 
proteins that actually mediate the silencing [13]. The miRISC post-transcriptionally 
represses gene expression by initiating decay of target mRNAs and/or inhibiting 
their translation. It achieves this by recognising and binding to specific sequences 
on the target mRNA, usually in its 3’UTR, that is complementary to the miRNA 
seed site (located at nucleotides 2–8 of the miRNA, at its 5′ end). If the mRNA is 
sufficiently complementary to the miRNA, it will be cleaved by the slicer AGO 
and these cleaved mRNA fragments targeted for degradation [14, 15]. If binding is 
imperfect, AGO is unable to cleave the mRNA. However, complementary binding 
beyond the seed sequence can also initiate silencing; in this case the GW182 protein 
recruits deadenylation factors which destabilise the mRNA through the removal of 
its polyadenylated tail, again targeting it for degradation. Although the majority 
of miRNA-controlled gene silencing is achieved by mRNA cleavage or destabilisa-
tion, translation can also be repressed. This mechanism is less well understood but 
is thought to involve miRNA interaction with factors essential to the initiation of 
translation, such as cytoplasmic poly(A)-binding protein (PABPC) and cap-binding 
complex eIF4F [16].
While miRNA-mediated regulation is typically mild in nature, individual 
miRNAs can have significant and diverse biological effect due to their ability to 
target numerous different mRNA species within the same cell [17] and even several 
Figure 1. 
Overview of miRNA biogenesis and post-transcriptional repression mechanisms. MicroRNA genes are 
transcribed in the nucleus as primary transcripts (pri-miRNA) before being processed into ~70 nucleotide 
pre-miRNAs by Drosha endonuclease. The pre-miRNA is transported from the nucleus into the cytoplasm 
by Exportin-5 where it is processed further by dicer. The mature miRNA (red) is then loaded into Argonaute 
1–4 and assembled into the miRNA-induced silencing complex (miRISC), which is subsequently guided to 
the 3’UTR of the target mRNA. mRNA translation is inhibited by miRISC through one or more repressive 
mechanisms, including mRNA cleavage, degradation and translational repression.
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components within a single pathway [18]. Indeed, it is believed that the majority 
of protein-coding genes are regulated in some way by miRNAs given that >60% of 
human protein-coding genes contain a minimum of one conserved miRNA-binding 
site [19].
The naming of miRNAs follows a specific set of rules. Each miRNA name identi-
fies first its source species (e.g. ‘hsa’ for human and ‘mmu’ for mouse) and is num-
bered according to its order of submission to the miRNA database [20], with mature 
sequences labelled ‘miR’ and precursor hairpins ‘mir’ [21]. Identical sequences 
found in different species are assigned the same numbers, while identical sequences 
found within the same species but arising from different genomic locations are 
given numerical suffixes (e.g. hsa-miR-1-1, hsa-miR-1-2). miRNAs of similar 
sequence are grouped into a miRNA ‘family’ and are allocated an additional lower-
case letter to aid identification (e.g. hsa-miR-320a, hsa-miR-320b, hsa-miR-320c). 
Finally, given that mature miRNAs derive from a ‘hairpin’ precursor, the current 
nomenclature assigns either a -5p or -3p suffix, depending upon whether the 
miRNA was generated from the 5′ or 3′ arm of that hairpin (e.g. hsa-miR-34c-5p 
and hsa-miR-34c-3p).
4. Extracellular microRNAs
In addition to acting within the cell where they are transcribed, miRNAs can be 
released from those cells and have been detected in various bodily fluids, includ-
ing the bloodstream. This has raised interest in the potential utility of circulating 
miRNAs as disease biomarkers [22, 23]. The majority of miRNAs within the cir-
culation are associated with AGO2 in nuclease-resistant complexes. miRNAs also 
circulate within exosomes, which are small membrane vesicles that form within 
multivesicular bodies and are secreted upon fusion with the plasma membrane. 
Exosomes contain specific miRNAs rather than the complete spectrum of miRNAs 
of a cell, indicating as yet unknown mechanisms for their recognition, packaging 
and secretion. miRNAs may also be incorporated into high-density lipoprotein 
and low-density lipoprotein particles although this process is again not fully 
understood. Secreted miRNAs can, in principle, be transferred from one tissue to 
another through the circulation, but it is unclear whether a miRNA species taken 
up by a cell in this way can achieve sufficient levels to inhibit its target transcripts 
significantly. This mechanism of action raises the intriguing possibility that extra-
cellular  miRNAs participate in long-range signalling between tissues, in a manner 
analogous to endocrine systems. In this regard, miRNAs have been reported to act 
as agonists of Toll-like receptors and to trigger downstream pathway activation in 
target cells [24]. Distinctive expression patterns of extracellular miRNAs have also 
been associated with a variety of cardiovascular disorders, including atheroscle-
rosis, myocardial infarction, heart failure, hypertension and type 2 diabetes [22]. 
However, whether these miRNAs participate in the disease process or simply serve 
as markers of disease progression has not been established. Greater patient cohorts 
will be needed to reach firm conclusions regarding the diagnostic and prognostic 
power of extracellular miRNAs.
5. MicroRNAs and corticosteroid production
Various studies have demonstrated the importance of microRNAs to adrenal 
development and maintenance in animal models [25, 26], but their effects on the 
human adrenal gland are less well defined. As far as secretion of corticosteroids 
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such as aldosterone is concerned, miRNAs could have direct influence through 
the post-transcriptional repression of corticosteroidogenic or other related 
genes, which has been investigated. In 2008, Romero et al. identified miR-21 as 
a key modulator of aldosterone production. Overexpression of miR-21 in vitro 
significantly increased aldosterone production and cell proliferation in the H295R 
human adrenocortical carcinoma cell line [27]. These findings supported a role for 
miR-21 in both corticosteroid production and oncogenesis but possible target genes 
of miR-21 or a regulatory mechanism by which it increases aldosterone produc-
tion and cell proliferation were not described. However, subsequent studies have 
demonstrated that miRNAs target numerous stages of the aldosterone biosynthesis 
pathway.
We have carried out comprehensive analysis of miRNA effects on aldosterone 
and cortisol production, as well as identifying and confirming target genes. We 
used a siRNA approach to knock down expression of Dicer, the protein essential to 
miRNA maturation, in H295R cells and studied its effects on cellular levels of ste-
roidogenic mRNAs. Interestingly, only those encoding cytochrome P450 enzymes in 
the pathway (CYP11A1, CYP21A1, CYP17A1, CYP11B1, CYP11B2) were significantly 
increased in the absence of miRNA [28, 29]. Steroid production was also corre-
spondingly changed, with levels of the end products aldosterone and cortisol—as 
well as many intermediate compounds in their biosynthesis—all increased relative 
to control cells (DOC, corticosterone, 18-OH corticosterone).
We then used a combination of bioinformatic prediction and experimental 
in vitro experimentation in H295R cells to confirm miRNA-24 as a direct regula-
tor of CYP11B1 and CYP11B2 expression via sites in the mRNA 3’UTRs. We also 
observed changes in aldosterone and cortisol production rates that correlated with 
miRNA-altered levels of CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone 
synthase). These experimental results were consistent with canonical miRNA 
action, whereby reduced levels of the mature miRNA result in less target mRNA 
degradation and therefore more abundant steroid product due to higher gene 
expression. These data therefore demonstrated a significant regulatory role for 
miRNAs in human steroidogenesis. Furthermore, other studies show miR-24 to 
be upregulated following MR activation in the kidney, leading to the proposal that 
it might form part of a feedback loop to the adrenal gland, repressing CYP11B2 
expression when aldosterone levels are high [30].
Subsequent studies have expanded the array of miRNAs known to regulate 
directly the expression of late enzymes in this pathway: Nusrin and colleagues 
showed that miR-10b also negatively regulates both CYP11B1 and CYP11B2 expres-
sions in H295R cells, subsequently modulating aldosterone and cortisol production 
[31]. We found that miRNAs -125a-5p and -125b-5p modulate CYP11B2 (but not 
CYP11B1) in H295R cells [29], as did Maharjan et al. with miR-766 [32], although 
either study determined the effect of this on aldosterone production or whether 
cortisol remains unaffected. Looking to steroidogenic enzymes earlier in the 
pathway, we demonstrated a direct regulatory effect of miR-320a-3p on CYP11A1 
and CYP17A1 in H295R cells [29]. Furthermore, Hu and colleagues reported that 
miR-132 regulates steroidogenesis by inhibiting StAR protein expression, thereby 
inhibiting basal progestin production and stimulating 20α-OHP production in 
Y1 mouse adrenocortical cells [33]. They also demonstrated a secondary method 
of miR-132 regulation in Y1 cells, through which miRNA overexpression reduces 
methyl-DNA-binding (MECP2) protein and alters levels of 3β-HSD and 20α-HSD; 
this stimulates the conversion of progesterone to its inactive metabolite, 20α-OHP 
{Hu:2017iz}. The same group also showed negative regulation of HDL cholesteryl 
ester uptake and HDL-stimulated progesterone production by miR-125a and 
miR-455, acting via scavenger receptor class B type I (SR-B1), although this work 
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was primarily carried out in Leydig testicular cells {Hu:2012by}. It is therefore clear 
that miRNAs—including those mentioned above and likely many more, as yet 
 undiscovered—regulate steroidogenesis within the adrenal cortex, at many differ-
ent points, although the full impact of these individual regulatory miRNAs acting 
concurrently across the entirety of the corticosteroid pathway is yet to be assessed.
Studies have also expanded to examine non-steroidogenic genes with regula-
tory influence. Decreased expression of TWIK-related acid-sensitive K+ (TASK-2) 
channels is associated with increased CYP11B2 and StAR expression and with raised 
aldosterone levels; miR-34 and miR-23 reduce TASK-2 expression by direct bind-
ing of its mRNA 3’UTR [34]. Regulation of RAS genes by the miRNA has also been 
shown, with miR-181a and miR-663 both binding the 3’-UTR of the renin transcript 
[35]. The same study showed both of these miRNAs to be downregulated in the 
renal cortex of hypertensive subjects relative to normotensives, providing a pos-
sible mechanistic factor. Separately, miR-483 has been shown to repress four RAS 
components, including angiotensinogen [18]. Furthermore, angiotensin II (AngII) 
causes downregulation of miR-483 itself in vascular smooth muscle cells, implying 
that RAS activation could derepress itself through reduction of miR-483.
In addition to understanding which miRNAs target which elements of corti-
costeroid production and regulation, if miRNA-mediated control is to be fully 
understood, then we must improve our understanding of how production of the 
individual miRNAs is itself regulated. It is intuitively obvious that levels of these 
miRNAs should fluctuate in response to physiological demands and there are 
plentiful instances of this from various studies. Of the miRNAs already mentioned 
here, it is known that miR-21 expression is increased in H295R cells following 
angiotensin II stimulation [27], that miR-10b levels increase in response to hypoxia 
in H295R cells [31] and that miR-212 and miR-132 are more abundant in adrenal 
cells in vitro and the adrenal gland in vivo in response, respectively, to cAMP and 
ACTH  stimulation [33].
6. Adrenal microRNAs
Numerous studies have profiled circulating or adrenal tissue miRNA expression 
in patients with adrenal carcinoma and/or aldosterone-producing adenoma (APA), 
confirming that miRNA expression is altered by these conditions relative to healthy 
controls [28, 29, 34, 36–51].
Notably, of the 11 miRNAs that have been shown to regulate corticosteroid 
biosynthesis in adrenal tissue (above), 8 are dysregulated in patients with benign 
adenoma or adrenal carcinoma: miRNAs -10b, −24 and -125a are downregulated 
in APA tissue [28, 29]; miR-125b is downregulated in carcinoma vs. benign adrenal 
tumour tissue [43]; miR-21, miR-320a-3p and miR-34 are significantly increased 
in adenoma tissue [28, 29, 41] and miR-21 is further increased in carcinoma tissue 
[41]; serum levels of miR-34a are raised in patients with adrenocortical carcinoma 
relative to patients with benign adrenocortical neoplasm [42]. TASK-2 expression 
is reduced in APA tissue relative to healthy adrenal tissue and negatively correlates 
with miR-23 and miR-34 levels [34]. Given that APA increases aldosterone secre-
tion, it is perhaps unsurprising that miRNAs known to modulate corticosteroid 
biosynthesis, such as miR-24, show altered expression. Interestingly, one of the two 
genomic locations from which miR-24 is transcribed is a cluster on chromosome 9, 
where miR-24 is produced alongside miR-23b and miR-27b; our studies show all 
three to be downregulated in APA, which is consistent with this clustering and 
implies that many and diverse biological effects could result from the change in 
regulation to all three microRNAs [28]. Overall, existing studies of miRNA changes 
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in adrenal tumours add weight to the hypothesis that miRNA targeting of tran-
scription is a common feature of such conditions and is likely to be of relevance to 
adrenal pathology generally.
Expression of several other miRNAs has also been found to be altered in multiple 
independent studies of adrenal disease. Most notably miR-483 is increased in tumour 
[36, 38, 41, 43, 47] and circulating (i.e. plasma or extracellular vesicle) [38, 42, 44, 48] 
samples from patients with adrenocortical carcinoma when compared to samples 
from patients with adrenocortical adenomas or healthy controls. miR-210 [37, 41, 
48, 49] and miR-184 [48, 49] levels are also increased in tumour and plasma samples 
from patients with adrenocortical carcinoma in comparison to patients with adreno-
cortical adenoma or healthy controls and in some cases are increased in adrenocortical 
adenoma vs. healthy controls [41]. Other miRNAs are downregulated in tumour and 
serum samples of patients with adrenocortical carcinoma or adrenocortical adenoma 
relative to patients with adrenocortical adenoma or to healthy controls, respectively: 
these include miR-195 [38, 41, 43, 47] and miR-335 [38, 47]. However, little work 
has been done to assess the biological impact of these miRNAs on the regulation of 
corticosteroid biosynthesis in the context of these diseases, and this remains an obvi-
ous priority area of future study. Clearly defined miRNA profiles that are specific to 
certain tumour types clearly have the potential to facilitate and expedite the differen-
tial diagnosis of adrenocortical tumours and enhance our understanding of disease 
pathogenesis (reviewed by Singh et al.) [52].
7. MicroRNA and the mineralocorticoid receptor
As the nuclear receptor to which aldosterone binds in all aldosterone-responsive 
tissues, the mineralocorticoid receptor is clearly a key factor in mediating the hor-
mone’s effects and is itself subject to miRNA regulation. In silico analysis predicts 
the NR3C2 gene, which encodes the MR and contains between 23 and 411 distinct 
miRNA-binding sites in its 3’UTR, depending on the prediction algorithm utilised. 
Of these predicted miRNAs, five were selected for further experimental validation; 
two—miRNA-124 and miRNA-135a—were subsequently confirmed to bind the 
NR3C2 3’UTR, as evidenced by a reduction in luciferase activity following NR3C2 
3′UTR luciferase reporter and miRNA expression vector cotransfection. Neither 
miRNA decreased NR3C2 mRNA level, suggesting miRNA-124 and miRNA-135a are 
involved solely in translational inhibition of MR [53]. Interestingly, miRNA-124 has 
also been identified as a regulator of the glucocorticoid receptor (GR), associated 
with cortisol action [54]. Given its brain-specific expression [55], miRNA-124 can-
not directly influence aldosterone biosynthesis but may have a role in the regulation 
of its production and action through centrally mediated systems. It is currently the 
subject of much investigation in light of its apparently beneficial effects post-stroke 
[56–59]. A role in neuronal differentiation has been proposed, and it is possible that 
the beneficial effects of miRNA-124 are achieved through downregulation of MR 
expression or activation, mirroring the beneficial effects of MR antagonists.
In addition to demonstrating that MR is regulated by miRNA, other studies 
identify MR as a mediator of miRNA expression. For example, aldosterone treat-
ment of aortal or vascular smooth muscle cells (SMCs) causes downregulation 
of miRNA-29b, but this effect can be prevented through MR blockade with the 
antagonist eplerenone [60]. Interestingly, this MR-regulated change does not occur 
in mouse endothelial cells, which demonstrates the cell specificity of this MR effect 
in the vasculature. As with miRNA-124, the benefits of miRNA-29b delivery to the 
brain post-stroke is currently being investigated [61, 62], although other reports 
suggest it may actually promote neuronal cell death [63].
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Another key factor in MR action is the enzyme 11β-hydroxysteroid dehydroge-
nase type 2 (11β-HSD2). As cortisol is capable of binding MR and circulates at levels 
far higher than aldosterone, 11β-HSD2 effectively confers aldosterone selectivity 
on tissues where it is expressed (such as the renal tubule), by converting cortisol 
to inactive cortisone; this leaves aldosterone free to bind MR without significant 
competition. 11β-HSD2 activity is therefore important, and its loss can result in 
salt-sensitive hypertension. Although direct inhibition of 11β-HSD2 expression 
by miRNAs targeting the 3’UTR of its mRNA has been demonstrated in rats, the 
existence and importance of such regulation in human aldosterone-selective tissues 
is yet to be confirmed [64].
Despite the various inconsistencies and gaps in our current knowledge, such 
ongoing studies of miRNA targeting, action and expression are likely to provide 
valuable insights into aldosterone action in the future.
8.  MicroRNAs as biomarkers and therapeutic targets in endocrine 
pathologies
Excessive aldosterone production and the consequent activation of MR are now 
generally accepted to be important and common factors in the pathogenesis of 
hypertension and a number of related comorbidities. Given that specific changes 
in miRNA expression and regulation are associated with certain disease states and 
that miRNAs can be released into extracellular fluids, the potential exists to use 
circulating microRNAs as biomarkers for conditions that are otherwise difficult 
to diagnose. This includes various endocrine pathologies, including PA, where 
the difficulty of accurately identifying and distinguishing aldosterone-producing 
adenoma and bilateral adrenal hyperplasia (BAH) is acknowledged to have 
restricted diagnosis and effective treatment. Given that miRNAs are known to 
regulate corticosteroid biosynthesis and that adrenal miRNA expression is altered 
in cases of adrenal pathology, it is reasonable to hypothesise that changes in the 
array of circulating miRNAs might result from diseases affecting corticosteroid 
regulation or other forms of adrenal function. A current ongoing initiative in this 
regard—which arose in part from the COST ADMIRE network—is the ENS@T-HT 
study. This is an EU-funded Horizon 2020 research and innovation project designed 
to define specific ‘omics’ for various forms of endocrine hypertension, including 
PA, Cushing’s syndrome and phaeochromocytoma. Our particular focus as part of 
this project has been the profiling of circulating miRNAs in patient plasma, with the 
aim of identifying signature miRNAs of diagnostic value. Initial miRNA profiling 
has now been completed in archived samples, and analysis is under way to develop 
a signature for testing in a new study population. This study is part of a wave of 
current diagnostic initiatives aiming to improve diagnosis and better target patient 
treatment through a stratified medicine approach. MicroRNA is likely to be a focus 
of many such projects which share the implicit assumption that if miRNA profile is 
altered by disease, then manipulation of miRNA might also form part of an effective 
treatment. The longer-term aspiration of such studies— including ENS@T-HT—is 
therefore the progression from diagnostic applications to therapeutics.
The therapeutic potential of miRNAs is derived from the ability to inhibit 
miRNA function with antimiRs. These are small oligonucleotides that can be 
delivered subcutaneously or intravenously and inhibit the interaction of miR-
NAs with their targets by binding the miRNA seed site with high affinity [65]. 
Pharmacokinetic and pharmacodynamic studies of antimiR action suggest they are 
taken up from the circulation by endocytosis and accumulate within endosomes or 
multivesicular bodies, but much remains unknown about the precise mechanisms 
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of action and cellular handling of antimiRs. In contrast to classical drugs, the action 
of antimiRs appears to be delayed, often taking several days to exert an effect. This 
reflects the time required to rebalance the proteome of a target cell as a consequence 
of the relatively modest changes in numerous miRNA targets. Conversely, the 
actions of antimiRs are long-lived, owing to their high stability and accumulation 
within intracellular depots from which they are slowly released. They show efficacy 
at doses acceptable for therapeutic development, and further chemical modifica-
tions may enhance their uptake, stability and/or action.
An additional challenge with respect to the development of miRNA-based drugs 
is the inability to correlate target engagement with mechanism and therapeutic 
efficacy. Because of their many targets and the summation of relatively small 
repressive effects that contribute to the therapeutic actions of miRNAs, it is dif-
ficult or impossible to directly ascribe the activity of an antimiR to a specific target. 
An individual miRNA may have a beneficial activity in one tissue and an adverse 
activity in another. Therefore local delivery systems are likely to be useful in reduc-
ing off-target effects. While the sustained activity of antimiRs allows for effective 
treatment, the long-term consequences of antimiR accumulation in different tissues 
and the inability to rapidly reverse their activity or eliminate the presence of a toxic 
antimiR raise obvious concerns. AntimiRs accumulate predominantly in the liver 
and kidney, necessitating substantially higher doses to achieve efficacy in other tis-
sues. This poses challenges with respect to achieving sufficient intracellular concen-
trations that evoke a therapeutic effect without causing liver and renal toxicity.
Of course, miRNAs may also play beneficial rather than pathogenic roles so 
strategies for elevating their levels are also required, including the administration 
of miRNA mimics. These are double-stranded synthetic oligonucleotides that are 
processed into single-stranded miRNAs when introduced into cells. However, the 
delivery of miRNA mimics still requires significant optimisation [66]. Lipid for-
mulations for enhancing uptake may help in this regard, while adenoviral delivery 
methods may assist targeting to the tissue of choice. As with antimiRs, though, it is 
crucial to avoid repression of nontarget mRNAs or toxic accumulation of mimics.
Finally, a further factor needs to be considered regarding miRNA and its role 
in the personalisation or stratification of diagnosis and therapy: genetic polymor-
phisms. Although single-nucleotide polymorphisms that occur in protein-encoding 
or upstream regulator regions of genes are commonly accepted to contribute—
sometimes dramatically—to disease phenotype, it is increasingly recognised that 
polymorphisms in miRNA genes themselves or in those transcribed but untrans-
lated regions of the genes that they target might contribute to interindividual 
phenotypic variability and possibly predispose to disease [67]. This may become a 
major factor in the future ‘personalisation’ of medicine and effective targeting of 
therapeutic agents.
9. Conclusion
MiRNAs are providing us with fresh insights into aldosterone regulation, action 
and pathology while offering the prospect of new diagnostic and therapeutic 
approaches. It is apparent that miRNAs are important regulators of adrenal func-
tion and have the ability to regulate the expression of multiple enzymes within the 
corticosteroidogenic pathway, modifying the steroid profile as a result. Consistent 
changes in miRNA expression in APA or adrenocortical carcinoma tissue relative 
to healthy controls imply a role in the pathogenesis of these diseases and/or their 
resulting dysregulation. While the effect of each individual miRNA may be small, 
as numerous miRNAs can target the steroidogenic pathway in the adrenal cortex 
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and are altered in disease, the sum of multiple small individual effects could result 
in significant changes to corticosteroid synthesis within the adrenal cortex. The 
specificity with which miRNAs target their effect is potentially mirrored by the 
specificity with which dysregulated miRNAs might themselves be therapeutically 
targeted. The ability to do so raises the tantalising possibility of a new generation of 
therapeutic ‘magic bullets’. However, much remains to be learned about the precise 
mechanisms by which an individual miRNA affects different physiological path-
ways within single and different tissues and cell types. This may add significantly 
to the complexity and consequences of manipulating miRNA for therapeutic ends. 
A deeper understanding as well as a ‘systems biology’ approach is required to fully 
explain miRNA activity under conditions of homeostasis and disease. Despite these 
challenges and uncertainties, it seems likely that some of the numerous miRNAs 
currently implicated in cardiovascular disease will eventually emerge as viable 
biomarkers and possibly drug targets, although the timescale and the reach of such 
miRNA-based approaches cannot yet be predicted.
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